The laboratory of hygiene that shaped modern immunology
In short: Before it was a powerhouse of global health, the NIAID began as a small laboratory in New York. Its mission was simple: study the link between microscopic organisms and disease. Today, it remains a cornerstone of American science, evolving from a local
As a primary branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) focuses on the prevention, treatment, and study of allergic, immunologic, and infectious conditions. Its reach is global, funding research at institutions across the United States and the world, and collaborating with academia, industry, and government to tackle emerging threats like the COVID-19 and H1N1/09 pandemics.
The institute's lineage dates back to 1887, when medical officer Joseph J. Kinyoun established a "laboratory of hygiene" at the Marine Hospital on Staten Island. Relocated to Washington, D.C., this site became the Hygienic Laboratory in 1891 after receiving Congressional permission to examine public health issues. The Ransdell Act of 1930 eventually transformed it into the National Institute of Health. It wasn't until 1955 that the name was changed to NIAID to reflect its expanded focus on allergy and immunology.
NIAID has a storied history of practical medical advancement. It was instrumental in the development and licensure of several FDA-approved vaccines, including those for influenza (FluMist), hepatitis A (Havrix), and rotavirus (RotaShield). It also played a critical role in developing acellular pertussis vaccines and preventive therapies for respiratory syncytial virus (RSV). Beyond vaccines, the institute has pioneered diagnostic tests for malaria, tuberculosis, and norovirus.
Research at NIAID also addresses significant global health disparities. For instance, NIAID-funded studies in Uganda in 1999 demonstrated that inexpensive drugs like nevirapine could reduce mother-to-child transmission of HIV by half. More recent NIAID-funded findings showed that infants diagnosed with HIV who received antiretroviral therapy (ART) immediately were four times less likely to die compared to those who waited for symptoms to appear. These findings were pivotal in influencing World Health Organization guidelines for pediatric HIV care.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: National Institute of Allergy and Infectious Diseases
- Also: PloS one — Outcomes of early NIH-funded investigators: Experience of the National Institute of Allergy and Infectious Diseases. · CC CC0
- Also: www.usa.gov — National Institute of Allergy and Infectious Diseases (NIAID) | USAGov
To cite this card, link to https://intellectplus.co.uk/app/health-national-institute-of-allergy-and-infectious-diseases.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Vaccines · More in Health · Latest · A–Z · All topics
